Breakthrough Cancer Treatment: Darzaxatrasib Shows Promise Against Pancreatic Cancer
On this week’s frontiers of oncology, darovasertib (previously called ATR inhibitor)—a first-in-class targeted therapy—has emerged as a potential game-changer for metastatic pancreatic ductal adenocarcinoma (PDAC), the deadliest form of pancreatic … Read More